The European Patent Office (EPO) has granted patent EP3609527B1, effective March 18, 2026, for "Protein Conjugates." This patent covers specific chemical and biological compositions and methods related to protein conjugates, including those used in therapeutic applications like cancer treatment. The grant signifies that the EPO has found the invention to be novel, inventive, and industrially applicable within its jurisdiction.

This patent grant establishes exclusive rights for the patent holder within the designated European states. Companies operating in the biotechnology and pharmaceutical sectors, particularly those involved in developing or utilizing protein conjugate technologies, should review the patent claims to ensure they do not infringe on the granted intellectual property. Compliance officers should assess any existing or planned activities related to protein conjugates against the scope of this patent to avoid potential legal challenges.